Clinical outcome of gemcitabine (gem)/cisplatin (cis)- vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age

• DOI: 10.1200/jco.2006.24.18_suppl.7055
• Publication Date: 2020-03-09T19:55:53Z
• Authors: R. Rosell-Costa; V. Alberola; C. Camps; G. Lopez-Vivanco; T. Moran; O. Etxaniz; R. De Las Peñas; J. Gupta; M. Taron; J. Sanchez
• Keywords: XRCC3; XRCC1

7055 Background: Significant interaction between XRCC1 genotype and age has been reported, with younger subjects having a greater risk of developing lung cancer. Carriers XRCC3 241 MetMet have higher levels DNA adducts, leading us to hypothesize that they would be more chemosensitive, especially patients. Methods: Real-time PCR assay was used determine from isolated baseline blood samples 878 stage IV NSCLC p (162 treated gem/cis; 716 doc/cis). Median age, 60; 266 (30%) <55; 239 (39%) 55–66; 273 (31%) >66. Adenocarcinoma: 459 (53%). Homozygous variant found in 124 (14%), the same frequency each three groups. Results: After median follow-up 7.6 months (m) (95% CI, 1–47 m), overall survival (MS) 9.5 m 8.8–10.2 no differences 2 regimens. In all MetMet, MS 12.9 for gem/cis 8.4 doc/cis (P = 0.06) (hazard ratio at y 0.23). <55 y, not reached 9.2 0.02), which translated into 60% difference y. This diminished 55–66 (MS gem/cis, 6.9 [P 0.09]; 28% y) disappeared >66 5.8 7.8 0.55]. For other genotypes (ThrThr ThrMet), were either or broken down by age. Conclusions: is both an easily assessable robust predictive marker gem/cis-treated p. The benefit dwindles increasing possibly related enhanced repair capacity older No significant financial relationships disclose.